Quick Answer
Selenium Immune Function Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: reported that 6 months of Sel improved GO-specific QoL, reduced ocular involvement, and slowed progression in patients with mild GO, supporting its incorporation into European guidance for mild, active GO, particularly in Sel-deficient areas [].
Key Takeaways
- 01reported that 6 months of Sel improved GO-specific QoL, reduced ocular involvement, and slowed progression in patients with mild GO, supporting its incorporation into European guidance for mild, active GO, particularly in Sel-deficient areas []. [Kostadinov Nikolay (2026)]
- 02Subsequent studies expanded the evidence base but introduced uncertainty: a Mexican randomized study suggested improved clinical activity and reduced progression in mild GO, whereas trials in Sel-sufficient settings and in inactive moderate-to-severe GO have reported more heterogeneous effects [,,]. [Kostadinov Nikolay (2026)]
- 03Current recommendations are largely influenced by limited trial evidence, and prior syntheses have not fully clarified whether benefits differ by baseline Sel status, GO activity/severity, treatment duration, or outcome domain. [Kostadinov Nikolay (2026)]
- 041 2 Graves’ orbitopathy (GO) is an immune-mediated inflammatory disorder of the orbit and periorbital tissues and represents the most common extrathyroidal manifestation of Graves’ disease. [Kostadinov Nikolay (2026)]
The current Migaku evidence database contains 2 reusable source documents for Selenium Immune Function Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- reported that 6 months of Sel improved GO-specific QoL, reduced ocular involvement, and slowed progression in patients with mild GO, supporting its incorporation into European guidance for mild, active GO, particularly in Sel-deficient areas []. [Kostadinov Nikolay (2026); evidence level 1]
- Subsequent studies expanded the evidence base but introduced uncertainty: a Mexican randomized study suggested improved clinical activity and reduced progression in mild GO, whereas trials in Sel-sufficient settings and in inactive moderate-to-severe GO have reported more heterogeneous effects [,,]. [Kostadinov Nikolay (2026); evidence level 1]
- Current recommendations are largely influenced by limited trial evidence, and prior syntheses have not fully clarified whether benefits differ by baseline Sel status, GO activity/severity, treatment duration, or outcome domain. [Kostadinov Nikolay (2026); evidence level 1]
- 1 2 Graves’ orbitopathy (GO) is an immune-mediated inflammatory disorder of the orbit and periorbital tissues and represents the most common extrathyroidal manifestation of Graves’ disease. [Kostadinov Nikolay (2026); evidence level 1]
- Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements. [Berisha-Muharremi V (2026); evidence level 1]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources